Company Encyclopedia
View More
name
First Trust Small Cap Growth AlphaDex
FYC.US
News
View More

Healthcare & Biotech Stocks Rally After Hours: Sensei, Praxis, Cooper, Vanda, Cue, ResMed

Several healthcare and biotech stocks saw significant gains in after-hours trading on Thursday due to clinical updates, earnings results, and regulatory developments. Sensei Biotherapeutics surged 62.9%, Praxis Precision Medicines rose 24.8%, CooperCompanies climbed 13.0%, Vanda Pharmaceuticals gained 7.5%, Cue Biopharma increased 7.8%, and ResMed added 3.7%. Key drivers included positive clinical trial results, earnings reports, and regulatory decisions.

rttnews·
US
SNSE
+21.38%
US
VNDA
-1.33%
US
PRAX
+2.05%
rttnews·
US
SNSE
+21.38%
US
VNDA
-1.33%
US
PRAX
+2.05%

Cidara Therapeutics (NASDAQ:CDTX) Sets New 1-Year High - Still a Buy?

Cidara Therapeutics (NASDAQ:CDTX) reached a new 52-week high, trading at $220.74 with significant volume. Analysts have mixed ratings, with a consensus of "Hold" and a price target of $156.11. The company reported a quarterly EPS of ($1.43), missing estimates. Insider and institutional activities show changes in stock positions. Cidara focuses on developing therapies for serious diseases, including fungal infections.

Market Beat·
US
CDTX
-0.22%
Market Beat·
US
CDTX
-0.22%

CFO Bixby Surrenders 2,862 Of Lemonade Inc [LMND]

CFO Timothy E. Bixby of Lemonade Inc. surrendered 2,862 shares back to the company to cover option exercise costs and tax liabilities, as disclosed in a Form 4 filed with the SEC on December 4, 2025. The transaction was valued at $208,182, with shares priced at $72.74 each. Bixby's ending holdings are 251,625 shares directly.

Reuters·
US
LMND
+4.36%
Reuters·
US
LMND
+4.36%

Praxis Precision Medicines Reports Positive EMBOLD Study Results for Relutrigine in SCN2A and SCN8A Epileptic Encephalopathies

Praxis Precision Medicines announced positive results from the EMBOLD study on relutrigine for SCN2A and SCN8A epileptic encephalopathies. The study was stopped early due to efficacy, and results will be presented at the American Epilepsy Society Annual Meeting on December 6, 2025. Praxis plans to meet with the FDA to discuss the study results and potential NDA filing.

Reuters·
US
PRAX
+2.05%
Reuters·
US
PRAX
+2.05%

3 'Strong Buy' Stocks to Buy Today, 12/4/2025, According to Top Analysts

Top analysts recommend three 'Strong Buy' stocks: Praxis Precision Medicines (PRAX), Skyward Specialty Insurance Group (SKWD), and SailPoint (SAIL). PRAX has a 70.29% upside, SKWD a 44.31% upside, and SAIL a 40.58% upside. Analysts maintain Buy ratings with adjusted price targets. TipRanks offers tools for real-time analyst rankings and stock insights.

Tip Ranks·
US
PRAX
+2.05%
US
SKWD
+5.18%
US
SAIL
+2.21%
Tip Ranks·
US
PRAX
+2.05%
US
SKWD
+5.18%
US
SAIL
+2.21%
© 2025 Longbridge｜Disclaimer